Asterias Provides 24 Month Cohort 2 Update for its OPC1 Phase 1/2a Clinical Trial in Severe Spinal Cord Injury
Asterias Biotherapeutics Announces New Exclusive License Agreement with The Regents of the University of California
Asterias Biotherapeutics Granted Orphan Drug Designation for AST-OPC1 for the Treatment of Acute Spinal Cord Injury
Prismo Metals Announces Closing of Upsized Private Placement Silver King Exploration to Begin in July
